Making a Difference, Here & Beyond
The community invests in Dell Med. In return, it’s our responsibility — one we take seriously — to be agents for change and to show real impact.
OUR WORK
More Information
PARTICIPATE
COLLABORATE
Creating a New Kind of Doctor
We recruit and train physician leaders as comfortable taking on systemic challenges in health as caring for individual patients.
ARE YOU ONE?
Improving Care. Improving Health.
We’re here to make health — including health care — better. The end goal is a complete revolution in how people get and stay healthy.
WHAT IT MEANS
Discovery to Impact — Faster
We reward creative thinking and encourage rapid experimentation, using collaborative programs to speed promising research to market.
SEE HOW
More Information
Let’s Do Big Things Together
True health demands that the whole work in harmony, which is why we’re dedicated to partnership. Indeed, we can’t achieve our goals without it.
LEARN MORE
More Information
PARTICIPATE
Meet Dell Med
We’re rethinking the role of academic medicine in improving health — and doing so with a unique focus on our community.
ABOUT US
More Information
Make an Appointment Directory Give Faculty Students

John Powers, Ph.D.

Education

Ph.D.
University of Texas at Austin

About

John Powers, Ph.D., as an assistant professor of pediatrics at Dell Medical School working closely with the school’s Dell Pediatric Research Institute, Department of Oncology and LIVESTRONG Cancer Institutes; and with cancer researchers at the university’s College of Pharmacy.

Powers is an alumnus of UT Austin, where he received an undergraduate degree in Microbiology and earned his Ph.D. in Molecular Genetics and Microbiology. Previously, he was a Research Associate in the Division of Hematology/Oncology at Boston Children’s Hospital.

In his research, Powers focuses on understanding the underlying genetic mechanisms leading to pediatric neuroblastoma, a rare type of cancer that forms in certain types of nerve tissue and often affects young children. In the U.S., neuroblastoma accounts for approximately 6 percent of childhood cancers.

Poor prognosis in neuroblastoma is frequently driven by a gene with the potential to cause cancer known as MYCN. Powers’ research is focused on improving understanding of how this gene becomes amplified and dysregulated, a situation that leads to neuroblastoma.